What was the overall market valuation of the China neurodegenerative disease market in 2024?

The overall market valuation was $6.14 Billion in 2024. Read More

What is the projected market valuation for the China neurodegenerative disease market by 2035?

The projected valuation for 2035 is $13.76 Billion. Read More

What is the expected CAGR for the China neurodegenerative disease market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 7.6%. Read More

Which companies are considered key players in the China neurodegenerative disease market?

Key players include Biogen, Eli Lilly, Roche, Novartis, AstraZeneca, Merck & Co, Amgen, Sanofi, and Pfizer. Read More

What was the market valuation for Alzheimer's Disease in 2024?

The market valuation for Alzheimer's Disease was $1.54 Billion in 2024. Read More

What is the projected market size for Parkinson's Disease by 2035?

The projected market size for Parkinson's Disease by 2035 is $2.78 Billion. Read More

How much is the market for Multiple Sclerosis expected to grow by 2035?

The market for Multiple Sclerosis is expected to grow to $2.05 Billion by 2035. Read More

What are the main treatment types in the China neurodegenerative disease market?

Main treatment types include Medication, Therapy, Rehabilitation, and Surgical Interventions. Read More

What was the market size for Imaging Techniques in 2024?

The market size for Imaging Techniques was $2.05 Billion in 2024. Read More

What is the projected market size for the Transdermal route of administration by 2035?

The projected market size for the Transdermal route of administration by 2035 is $5.03 Billion. Read More

China Neurodegenerative Disease Market

ID: MRFR/MED/50859-HCR

200 Pages

Vikita Thakur

Last Updated: April 24, 2026

China Neurodegenerative Disease Market Research Report By Disease Type (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntington's Disease), By Diagnosis Method (Neurological Examination, Imaging Techniques, Cerebrospinal Fluid Analysis, Electrophysiological Tests), By Treatment Type (Medication, Therapy, Rehabilitation, Surgical Interventions) and By Route of Administration (Oral, Injectable, Intravenous, Transdermal) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Disease Type (USD Billion)
  1. 4.1.1 Alzheimer's Disease
  2. 4.1.2 Parkinson's Disease
  3. 4.1.3 Multiple Sclerosis
  4. 4.1.4 Amyotrophic Lateral Sclerosis
  5. 4.1.5 Huntington's Disease
2. 4.2 Construction, BY Diagnosis Method (USD Billion)
  1. 4.2.1 Neurological Examination
  2. 4.2.2 Imaging Techniques
  3. 4.2.3 Cerebrospinal Fluid Analysis
  4. 4.2.4 Electrophysiological Tests
3. 4.3 Construction, BY Treatment Type (USD Billion)
  1. 4.3.1 Medication
  2. 4.3.2 Therapy
  3. 4.3.3 Rehabilitation
  4. 4.3.4 Surgical Interventions
4. 4.4 Construction, BY Route of Administration (USD Billion)
  1. 4.4.1 Oral
  2. 4.4.2 Injectable
  3. 4.4.3 Intravenous
  4. 4.4.4 Transdermal
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Biogen (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Eli Lilly (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Roche (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AstraZeneca (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck & Co (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Amgen (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sanofi (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Pfizer (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 CHINA MARKET ANALYSIS BY DISEASE TYPE
3. 6.3 CHINA MARKET ANALYSIS BY DIAGNOSIS METHOD
4. 6.4 CHINA MARKET ANALYSIS BY TREATMENT TYPE
5. 6.5 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY DISEASE TYPE, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY DISEASE TYPE, 2024 TO 2035 (USD Billion)
14. 6.14 CONSTRUCTION, BY DIAGNOSIS METHOD, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Billion)
16. 6.16 CONSTRUCTION, BY TREATMENT TYPE, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
18. 6.18 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.2.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

China Construction Market Segmentation

Construction By Disease Type (USD Billion, 2025-2035)

Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Huntington's Disease

Construction By Diagnosis Method (USD Billion, 2025-2035)

Neurological Examination
Imaging Techniques
Cerebrospinal Fluid Analysis
Electrophysiological Tests

Construction By Treatment Type (USD Billion, 2025-2035)

Medication
Therapy
Rehabilitation
Surgical Interventions

Construction By Route of Administration (USD Billion, 2025-2035)

Oral
Injectable
Intravenous
Transdermal

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”